This study investigated the feasibility of repurposing statins for targeting CD34+ cells in CML and consequently enhancing the DMR rate in patients with CML undergoing TKI therapy (Figure S1). Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.